# EDGAR Filing Document

**Accession Number:** 0001627223
**File Stem:** 0000950170-25-103204
**Filing Date:** 2025-8
**Character Count:** 94239
**Document Hash:** e4582030eba1b3122e8fb9fa23eb37c2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-103204.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0000950170-25-103204

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20250805

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chemours Co
- **CENTRAL INDEX KEY:** 0001627223
- **STANDARD INDUSTRIAL CLASSIFICATION:** CHEMICALS & ALLIED PRODUCTS [2800]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 464845564
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36794
- **FILM NUMBER:** 251186002

**BUSINESS ADDRESS:**
- **STREET 1:** 1007 MARKET STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** 302 773 1000

**MAIL ADDRESS:**
- **STREET 1:** 1007 MARKET STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chemours Company, LLC
- **DATE OF NAME CHANGE:** 20141205

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM** 8-K

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

August 5, 2025

Date of Report (Date of Earliest Event Reported)

![img173611355_0.jpg](img173611355_0.jpg)

The Chemours Company

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| Delaware | 001-36794 | 46-4845564 |
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer |
| Of Incorporation) | File Number) | Identification No.) |

---

1007 Market Street

Wilmington**,** Delaware 19801

(Address of principal executive offices)

Registrant's telephone number, including area code: (302) 773-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of Each Class** | **Name of Exchange on Which Registered** |
| Common Stock ($0.01 par value)<br> CC | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On August 5, 2025, The Chemours Company (the "Company") issued a press release regarding its second quarter 2025 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. Senior management's prepared remarks are attached as Exhibit 99.2 to this report. The Company will post to its investor relations website, investors.chemours.com, an investor presentation and prepared remarks by 8:00 a.m. Eastern Daylight Time on Wednesday, August 6, 2025, for its conference call scheduled for that time.

The information furnished with this report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it will not be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1 [<u>Press release dated August 5, 2025.</u>](cc-ex99_1.htm)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.2 [<u>The Chemours Company Q2 2025 Financial Results Conference Call Prepared Remarks dated August 5, 2025.</u>](cc-ex99_2.htm)

104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| THE CHEMOURS COMPANY | THE CHEMOURS COMPANY |
| By: | /s/ Shane Hostetter |
|  | Shane Hostetter |
|  | Senior Vice President, Chief Financial Officer |
| Date: | August 5, 2025 |

---

------

## Exhibit 99.1

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**The Chemours Company Reports Second Quarter 2025 Results**

**Wilmington, Del.,** August 5, 2025 – The Chemours Company ("Chemours" or "the Company") (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions ("TSS"), Titanium Technologies ("TT"), and Advanced Performance Materials ("APM"), today announced its financial results for the second quarter 2025.

**Key Second Quarter 2025 Results & Highlights**<sup>1</sup>

• Net Sales of $1.6 billion, a 4% increase compared to the corresponding prior-year quarter, with TSS achieving year-over-year growth of 65% in Opteon™ Refrigerants

• Net Loss attributable to Chemours of $381 million, or $2.54 per diluted share, compared with Net Income attributable to Chemours of $60 million, or $0.39 per diluted share, in the corresponding prior-year quarter

• Adjusted Net Income<sup>2</sup> of $87 million, or $0.58 per diluted share, compared to $58 million, or $0.38 per diluted share, in the corresponding prior-year quarter

• Adjusted EBITDA<sup>1,3</sup> of $253 million compared to $207 million in the corresponding prior-year quarter

• Agreement reached with the State of New Jersey to comprehensively resolve all statewide environmental claims, including those related to PFAS

• Declared a quarterly cash dividend of $0.0875 per share on the Company's common stock for the third quarter of 2025

*"Our results surpassed our expectations for the quarter, with improved performance across each of our three businesses driven by strong demand for Opteon™, volume growth in TT, and favorable pricing in APM. We also made significant progress against Pathway to Thrive through our Strengthening the Long Term pillar, reaching a settlement to comprehensively resolve all statewide environmental claims, including those related to PFAS in New Jersey," said Denise Dignam, Chemours President and CEO. "We also remain equally focused on the other key pillars in our strategy with an emphasis on Operational Excellence, considering recent operational headwinds as we work to drive an improved operating model to reduce business disruptions going forward."* 

**Total Chemours**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Q2 2025** | &nbsp;&nbsp;**Q2 2024** | &nbsp;&nbsp;**Y-o-Y % ∆** | &nbsp;&nbsp;**Q1 2025** | &nbsp;&nbsp;**Q-o-Q % ∆** |
| &nbsp;&nbsp;Net Sales *(millions)* | &nbsp;&nbsp;$1615 | &nbsp;&nbsp;$1554 | &nbsp;&nbsp;4% | &nbsp;&nbsp;$1368 | &nbsp;&nbsp;18% |
| &nbsp;&nbsp;Adjusted EBITDA *(millions)* | &nbsp;&nbsp;$253 | &nbsp;&nbsp;$207 | &nbsp;&nbsp;22% | &nbsp;&nbsp;$166 | &nbsp;&nbsp;52% |

---

Second quarter 2025 Net Sales were $1.6 billion, a 4% increase compared to the prior-year quarter. The increase in Net Sales was primarily driven by a 3% increase in volume and a 1% increase in price. The increase in volumes was primarily driven by increased Opteon™ Refrigerant blends volumes in TSS. Increased pricing was driven by stronger aftermarket demand for Opteon™ Refrigerant blends in TSS and strong pricing in APM's Advanced Materials portfolio, partially offset by TT pricing.

<sup>1</sup> As previously disclosed in the first quarter of 2025, certain prior period amounts have been revised to correct for certain immaterial errors as further described in our Quarterly Report on Form 10-Q for the three months ended June 30, 2025.

<sup>2</sup> Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)".

<sup>3</sup>Adjusted EBITDA excludes net income attributable to noncontrolling interests, net interest expense, depreciation and amortization, and all remaining provision for income taxes from Adjusted Net Income. See the corresponding reconciliation referenced in footnote #2.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

Second quarter 2025 Net Loss attributable to Chemours was $381 million, or $2.54 per diluted share, compared to Net Income attributable to Chemours of $60 million, or $0.39 per diluted share in the prior-year quarter, primarily driven by litigation-related charges pertaining to the announced settlement with the State of New Jersey<sup>4</sup> and related tax impacts. Adjusted EBITDA for the second quarter of 2025 was $253 million, compared to $207 million in the prior-year quarter. The increase in Adjusted EBITDA was primarily driven by the referenced volume and pricing dynamics and lower Corporate Expenses. This was partially offset by higher input and operational costs in TT, lower fixed cost absorption in APM, and minor input cost increases in TSS.

**Thermal & Specialized Solutions**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Q2 2025** | &nbsp;&nbsp;**Q2 2024** | &nbsp;&nbsp;**Y-o-Y % ∆** | &nbsp;&nbsp;**Q1 2025** | &nbsp;&nbsp;**Q-o-Q % ∆** |
| &nbsp;&nbsp;Net Sales *(millions)* | &nbsp;&nbsp;$597 | &nbsp;&nbsp;$519 | &nbsp;&nbsp;15% | &nbsp;&nbsp;$466 | &nbsp;&nbsp;28% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Opteon™Refrigerants* | &nbsp;&nbsp;&nbsp;*$375* | &nbsp;&nbsp;&nbsp;*$227* | &nbsp;&nbsp;&nbsp;*65%* | &nbsp;&nbsp;&nbsp;*$279* | &nbsp;&nbsp;&nbsp;*34%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Freon™Refrigerants* | &nbsp;&nbsp;&nbsp;*$123* | &nbsp;&nbsp;&nbsp;*$173* | &nbsp;&nbsp;&nbsp;*(29)%* | &nbsp;&nbsp;&nbsp;*$97* | &nbsp;&nbsp;&nbsp;*27%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Foam, Propellants & Other (FP&O)* | &nbsp;&nbsp;&nbsp;*$99* | &nbsp;&nbsp;&nbsp;*$119* | &nbsp;&nbsp;&nbsp;*(17)%* | &nbsp;&nbsp;&nbsp;*$90* | &nbsp;&nbsp;&nbsp;*10%* |
| &nbsp;&nbsp;Adjusted EBITDA *(millions)* | &nbsp;&nbsp;$207 | &nbsp;&nbsp;$160 | &nbsp;&nbsp;29% | &nbsp;&nbsp;$141 | &nbsp;&nbsp;47% |
| &nbsp;&nbsp;Adjusted EBITDA Margin | &nbsp;&nbsp;35% | &nbsp;&nbsp;31% | &nbsp;&nbsp;4 ppts | &nbsp;&nbsp;30% | &nbsp;&nbsp;5 ppts |

---

TSS segment second quarter 2025 Net Sales were $597 million, a 15% increase compared to the second quarter 2024. Net Sales growth was primarily driven by a volume increase of 11% and a price increase of 4%, while currency impact remained flat. Volume growth was driven by stronger demand for Opteon™ Refrigerant blends in connection with the stationary air conditioning ("AC") transition under the U.S. AIM Act, partially offset by lower volumes for Freon™ Refrigerant products under this regulatory transition. The increase in pricing was primarily attributed to stronger Opteon™ Refrigerant aftermarket demand.

TSS segment second quarter 2025 Adjusted EBITDA increased 29% to $207 million compared to the prior-year quarter, while Adjusted EBITDA Margin also increased 4 percentage points to 35%. This increase was driven primarily by the previously mentioned increases in volume and price as a result of increased demand for Opteon™ Refrigerant blends products in connection with the stationary AC regulatory transition, partially offset by minor input cost increases.

On a sequential basis, Net Sales increased by 28%, driven by a volume increase of 19% and a price increase of 8%, with favorable currency movements adding a slight 1% tailwind. Overall volume and price increases were primarily related to typical seasonal trends across refrigerant products and the increased demand for Opteon™ Refrigerant blends in connection with the stationary AC transition under the U.S. AIM Act.

<sup>4</sup> $257 million of litigation-related charges pertaining to the announced settlement with the state of New Jersey were recorded within Selling, general, and administrative expense for the second quarter of 2025.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

**Titanium Technologies**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Q2 2025** | &nbsp;&nbsp;**Q2 2024** | &nbsp;&nbsp;**Y-o-Y % ∆** | &nbsp;&nbsp;**Q1 2025** | &nbsp;&nbsp;**Q-o-Q % ∆** |
| &nbsp;&nbsp;Net Sales *(millions)* | &nbsp;&nbsp;$657 | &nbsp;&nbsp;$677 | &nbsp;&nbsp;(3)% | &nbsp;&nbsp;$597 | &nbsp;&nbsp;10% |
| &nbsp;&nbsp;Adjusted EBITDA *(millions)* | &nbsp;&nbsp;$47 | &nbsp;&nbsp;$83 | &nbsp;&nbsp;(43)% | &nbsp;&nbsp;$50 | &nbsp;&nbsp;(6)% |
| &nbsp;&nbsp;Adjusted EBITDA Margin | &nbsp;&nbsp;7% | &nbsp;&nbsp;12% | &nbsp;&nbsp;(5) ppts | &nbsp;&nbsp;8% | &nbsp;&nbsp;(1) ppt |

---

TT segment second quarter 2025 Net Sales were $657 million, a 3% decrease compared to the second quarter 2024. This decrease was primarily driven by a 4% decrease in price globally, partially offset by favorable currency movements adding a slight 1% tailwind. Volumes remained generally flat overall, with stronger demand in North America and Europe offsetting lower volumes in other non-western markets.

TT segment second quarter 2025 Adjusted EBITDA decreased 43% to $47 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased five percentage points to 7%. The decline was driven in part by the previously mentioned decrease in price, partially offset by the favorable currency movements. TT operations were also disrupted by a now resolved external rail issue in the second quarter of 2025, which impacted feedstock mix, while also experiencing unrelated operational disruptions. In order to supply its customers, the Company elected to consume higher-cost ore feedstock, which resulted in incremental costs of $15 million in the second quarter. The net costs associated with other operational disruptions were $8 million for the quarter.

On a sequential basis, TT segment second quarter 2025 Net Sales increased 10%, driven by a 9% increase in volume across all regions, partially offset by a 1% decrease in price, with favorable currency movements adding a 2% tailwind.

 **Advanced Performance Materials**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Q2 2025** | &nbsp;&nbsp;**Q2 2024** | &nbsp;&nbsp;**Y-o-Y % ∆** | &nbsp;&nbsp;**Q1 2025** | &nbsp;&nbsp;**Q-o-Q % ∆** |
| &nbsp;&nbsp;Net Sales *(millions)* | &nbsp;&nbsp;$346 | &nbsp;&nbsp;$345 | &nbsp;&nbsp;0% | &nbsp;&nbsp;$294 | &nbsp;&nbsp;18% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Advanced Materials* | &nbsp;&nbsp;&nbsp;*$214* | &nbsp;&nbsp;&nbsp;*$212* | &nbsp;&nbsp;&nbsp;*1%* | &nbsp;&nbsp;&nbsp;*$178* | &nbsp;&nbsp;&nbsp;*20%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Performance Solutions* | &nbsp;&nbsp;&nbsp;*$132* | &nbsp;&nbsp;&nbsp;*$133* | &nbsp;&nbsp;&nbsp;*(1)%* | &nbsp;&nbsp;&nbsp;*$116* | &nbsp;&nbsp;&nbsp;*14%* |
| &nbsp;&nbsp;Adjusted EBITDA *(millions)* | &nbsp;&nbsp;$50 | &nbsp;&nbsp;$45 | &nbsp;&nbsp;11% | &nbsp;&nbsp;$32 | &nbsp;&nbsp;56% |
| &nbsp;&nbsp;Adjusted EBITDA Margin | &nbsp;&nbsp;14% | &nbsp;&nbsp;13% | &nbsp;&nbsp;1 ppt | &nbsp;&nbsp;11% | &nbsp;&nbsp;3 ppts |

---

APM segment second quarter 2025 Net Sales of $346 million were in line with the prior-year quarter. A 6% increase in price was offset by a 6% decrease in volume, while currency impact remained flat. The increase in pricing was primarily driven by stronger pricing in high-value applications as well as pricing opportunities associated with the SPS Capstone™ product line's exit<sup>5</sup>. The decrease in volume was primarily driven by weakness in cyclical end markets impacting Advanced Materials and products serving the hydrogen markets under Performance Solutions.

APM segment second quarter 2025 Adjusted EBITDA increased 11% to $50 million compared to the prior-year quarter, while Adjusted EBITDA Margin increased 1 percentage point to 14%. The increase was primarily due to the previously mentioned increase in price, partially offset by lower fixed cost absorption due to lower overall volumes.

<sup>5</sup> In January 2025, under the Portfolio Management pillar of Pathway to Thrive, as a part of a broader strategic review of our APM European asset footprint, APM management approved a restructuring program to exit its SPS Capstone™ business. This timing remains on track anticipating final sales in the third quarter of 2025.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

On a sequential basis, APM segment second quarter 2025 Net Sales increased by 18%, driven by a 14% increase in volume and a 2% increase in price, with favorable currency movements adding a 2% tailwind.

**Other Non-Reportable Segment**

The Performance Chemicals and Intermediates business in the Company's Other Non-Reportable Segment had Net Sales and Adjusted EBITDA for the second quarter 2025 of $15 million and $4 million, respectively.

**Corporate Expenses**<sup>6</sup>

Corporate Expenses were a $53 million offset to Adjusted EBITDA in the second quarter 2025, a decrease of $24 million compared to the prior-year quarter. This was primarily due to lower costs associated with the Audit Committee's internal review and the 2024 material weakness remediation.

**Agreement reached with the State of New Jersey to comprehensively resolve all statewide environmental claims, including those related to PFAS** 

On August 4<sup>th</sup>, 2025, Chemours, DuPont and Corteva, Inc. announced a settlement with the State of New Jersey to comprehensively resolve all environmental claims, including PFAS. This settlement resolves such matters across four current and former operating sites, providing for payments over 25 years with a net present value of approximately $250 million to Chemours. In connection with this settlement, earlier this week, Chemours also established an agreement with DuPont and Corteva to acquire Chemours' rights to certain PFAS-related insurance proceeds, providing $150 million to be used to fund the New Jersey settlement payments. The combination of this $150 million and the expected release of the approximately $50 million in restricted cash from the 2021 MOU escrow account is anticipated to fully fund Chemours' payment obligations under the New Jersey settlement through 2030. The present value of payments remaining after 2030 by Chemours for the New Jersey settlement is approximately $80 million prior to the consideration of additional PFAS-related insurance recoveries. Amounts related to the settlement are included in Selling, General and Administrative costs in the second quarter of 2025 and are excluded from Adjusted EBITDA.

**Liquidity and Capital Allocation**

As of June 30, 2025, consolidated gross debt was $4.2 billion. Debt, net of $502 million in unrestricted cash and cash equivalents, was $3.7 billion, resulting in a net leverage ratio of approximately 4.7x on a trailing twelve-month Adjusted EBITDA basis. Total liquidity was $1.5 billion, comprised of $502 million in unrestricted cash and cash equivalents and $954 million of revolving credit facility capacity, net of outstanding letters of credit.

Cash provided by operating activities for the second quarter of 2025 was $93 million, compared to operating cash usage of $620 million in the prior-year quarter. The improvement in operating cash flows in the second quarter of 2025 compared with the prior-year quarter was primarily due to the release of the $606 million of restricted cash and restricted cash equivalents deposited in the qualified settlement fund per the terms of the U.S. public water system settlement agreement.

Capital expenditures for the second quarter of 2025 amounted to $43 million, a decrease in spend compared to $73 million in the prior-year quarter, driven by lower capital expenditures in APM and TSS.

Free Cash Flows for the second quarter of 2025 reflected a positive $50 million. During the quarter, the Company paid $13 million in dividends to shareholders.

Effective August 5, 2025, the Company's Board of Directors declared a quarterly cash dividend of $0.0875 per share on the Company's common stock for the third quarter of 2025. The dividend will be paid on September 12, 2025, to stockholders of record as of the close of business on August 15, 2025.

<sup>6</sup> Second quarter 2025 consolidated Adjusted EBITDA also reflects additional unallocated costs of $2 million. These costs are reflected in consolidated Adjusted EBITDA results only.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

**Third Quarter 2025 Outlook**

In the third quarter, the Company anticipates consolidated Net Sales to decrease 4-6% sequentially, with consolidated Adjusted EBITDA expected to range between $175 million and $195 million. Corporate Expenses, as an offset to Adjusted EBITDA, are expected to decrease approximately 5%. The Company also anticipates capital expenditures to be approximately $50 million, with Free Cash Flow Conversion to be between 60-80%.

TSS expects a sequential Net Sales decrease in the mid single-digit percentage range, driven by overall traditional refrigerant seasonality concentrated in Freon™ Refrigerants. Adjusted EBITDA is also expected to decrease in the low-teens percentage range sequentially, primarily driven by the referenced seasonality as well as overall product mix.

TT expects a sequential Net Sales decrease in the low single-digit percentage range, driven by seasonality and regional sales mix, with volumes expected to remain stable. Adjusted EBITDA is also expected to decrease in the low-teens percentage range sequentially due to lower sales paired with certain operational disruptions. Costs associated with these operational issues are anticipated to approximate $15 million in the third quarter.

APM expects a sequential Net Sales decrease in the mid-teens percentage range due to production constraints associated with an outage at our Washington Works U.S. site. Adjusted EBITDA for APM is expected to approximate $15 million in the third quarter, considering lower sales as well as additional costs from the referenced site outage, which are anticipated to approximate $20 million.

**Full Year 2025 Outlook**

The Company expects to deliver Net Sales of $5.9 billion to $6.0 billion and Adjusted EBITDA of $775 million to $825 million in 2025, with referenced Q3 operational disruptions in TT and outage impacts in APM totaling $35M, collectively, to be resolved in the fourth quarter. Anticipated capital expenditures are expected to be approximately $250 million, with Free Cash Flow Conversion to be between 60-80% in the second half of 2025 through a seasonal net working capital unwind.

**Conference Call**

As previously announced, Chemours will hold a conference call and webcast on August 6, 2025, at 8:00 AM Eastern Daylight Time. The webcast and materials can be accessed by visiting the *Events & Presentations* page of Chemours' investor website, <u>investors.chemours.com</u>. A webcast replay of the conference call will be available on Chemours' investor website.

**About The Chemours Company**

The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 6,000 employees and 28 manufacturing sites and serves approximately 2,500 customers in approximately 110 countries. For more information, visit <u>chemours.com</u> or follow us on <u>LinkedIn</u>.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

**Non-GAAP Financial Measures**

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.

Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

**Forward-Looking Statements**

This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the second quarter of 2025, the full year 2025 and the Company's refreshed corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the US or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

------

**EXHIBIT 99.1**

![img15408389_0.jpg](img15408389_0.jpg)

![img15408389_1.jpg](img15408389_1.jpg)

**CONTACTS:**

**INVESTORS** <br>*Brandon Ontjes* <br>*Vice President, Head of Strategy & Investor Relations* <br>*+1.302.773.3309*

*<u>investor@chemours.com</u>* <br>

**NEWS MEDIA** <br>*Cassie Olszewski*<br>*Media Relations & Reputation Leader* <br>*+1.302.219.7140*<br>*<u>media@chemours.com</u>* 

------

**The Chemours Company**

**Consolidated Statements of Operations (Unaudited)**<sup>1</sup>

*(Dollars in millions, except per share amounts)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net sales | $1615 | $1554 | $2983 | $2915 |
| Cost of goods sold | 1337 | 1246 | 2469 | 2323 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 278 | 308 | 514 | 592 |
| Selling, general, and administrative expense | 437 | 154 | 560 | 292 |
| Research and development expense | 28 | 26 | 55 | 53 |
| Restructuring, asset-related, and other charges | 18 | 3 | 51 | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other operating expenses | 483 | 183 | 666 | 352 |
| Equity in earnings of affiliates | 9 | 11 | 17 | 23 |
| Interest expense, net | (67) | (66) | (133) | (128) |
| Other income (expense), net | 2 | (1) | 6 | 3 |
| **(Loss) income before income taxes** | (261) | 69 | (262) | 138 |
| **Provision for income taxes** | 119 | 9 | 122 | 25 |
| **Net (loss) income** | (380) | 60 | (384) | 113 |
| Less: Net income attributable to non-controlling interests | 1 |  | 1 |  |
| **Net (loss) income attributable to Chemours** | $(381) | $60 | $(385) | $113 |
| **Per share data** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic (loss) earnings per share of common stock | $(2.54) | $0.40 | $(2.56) | $0.76 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted (loss) earnings per share of common stock | (2.54) | 0.39 | (2.56) | 0.75 |

---

------

**The Chemours Company**

**Consolidated Balance Sheets (Unaudited)**<sup>1</sup>

*(Dollars in millions, except per share amounts)*

---

| | | |
|:---|:---|:---|
|  | **June 30, 2025** | **December 31, 2024** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $502 | $713 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable, net | 959 | 770 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 1558 | 1463 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other | 58 | 71 |
| &nbsp;&nbsp;&nbsp;&nbsp;Assets held for sale | 23 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 3100 | 3017 |
| Property, plant, and equipment | 9781 | 9572 |
| Less: Accumulated depreciation | (6660) | (6389) |
| &nbsp;&nbsp;&nbsp;&nbsp;Property, plant, and equipment, net | 3121 | 3183 |
| Operating lease right-of-use assets | 281 | 258 |
| Goodwill | 46 | 46 |
| Other intangible assets, net | 2 | 3 |
| Investments in affiliates | 177 | 152 |
| Restricted cash and restricted cash equivalents | 51 | 50 |
| Other assets | 710 | 804 |
| **Total assets** | $7488 | $7513 |
| **Liabilities** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $1023 | $1156 |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and other employee-related cost | 79 | 99 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term and current maturities of long-term debt | 38 | 54 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current environmental remediation | 102 | 115 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities | 608 | 393 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 1850 | 1817 |
| Long-term debt, net | 4102 | 4054 |
| Operating lease liabilities | 206 | 194 |
| Long-term environmental remediation | 503 | 456 |
| Deferred income taxes | 23 | 35 |
| Other liabilities | 565 | 369 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 7249 | 6925 |
| Commitments and contingent liabilities |  |  |
| **Equity** |  |  |
| Common stock (par value $0.01 per share; 810,000,000 shares authorized; 198,545,179 shares issued and 149,698,300 shares outstanding at June 30, 2025; 198,300,033 shares issued and 149,428,431 shares outstanding at December 31, 2024) | 2 | 2 |
| Treasury stock, at cost (48,846,879 shares at June 30, 2025 and 48,871,602 at December 31, 2024) | (1803) | (1804) |
| Additional paid-in capital | 1066 | 1055 |
| Retained earnings | 1265 | 1701 |
| Accumulated other comprehensive loss | (293) | (367) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Chemours stockholders' equity | 237 | 587 |
| Non-controlling interests | 2 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total equity | 239 | 588 |
| **Total liabilities and equity** | $7488 | $7513 |

---

------

**The Chemours Company**

**Consolidated Statements of Cash Flows (Unaudited)**<sup>1</sup>

*(Dollars in millions)*

---

| | | |
|:---|:---|:---|
|  | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
|  | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |
| Net (loss) income | $(384) | $113 |
| Adjustments to reconcile net income to cash used for operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 180 | 145 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sales of assets and businesses | (1) | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity in earnings of affiliates, net | (16) | (20) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs and issue discounts | 6 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax provision (benefit) | 84 | (15) |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset-related charges | 11 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 12 | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net periodic pension cost |  | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Defined benefit plan contributions | (8) | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other operating charges and credits, net | 14 | (18) |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease (increase) in operating assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable, net | (174) | (287) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories and other current operating assets | (42) | (9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-current operating assets | 64 | 52 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Decrease) increase in operating liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (87) | (175) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current operating liabilities | 83 | (690) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-current operating liabilities | 239 | (11) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash used for operating activities | (19) | (910) |
| **Cash flows from investing activities** |  |  |
| Purchases of property, plant, and equipment | (127) | (175) |
| Proceeds from sales of assets and businesses | 1 | 3 |
| Foreign exchange contract settlements, net | (2) | (1) |
| Other investing activities |  | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash used for investing activities | (128) | (171) |
| **Cash flows from financing activities** |  |  |
| Proceeds from issuance of debt, net | 95 |  |
| Debt repayments | (111) | (5) |
| Payments of debt issuance cost | (4) |  |
| Payments on finance leases | (7) | (6) |
| Proceeds from supplier financing program | 47 | 47 |
| Payments to supplier financing program | (53) | (61) |
| Proceeds from exercised stock options, net |  | 8 |
| Payments related to tax withholdings on vested stock awards | (1) | (3) |
| Payments of dividends to the Company's common shareholders | (50) | (74) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash used for financing activities | (84) | (94) |
| Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents | 21 | (13) |
| **Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents** | (210) | (1188) |
| **Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1,** | 763 | 1807 |
| **Cash, cash equivalents, restricted cash and restricted cash equivalents at June 30,** | $553 | $619 |
| **Supplemental cash flows information** |  |  |
| Non-cash investing and financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant, and equipment included in accounts payable | $26 | $44 |

---

------

**The Chemours Company**

**Segment Financial and Operating Data (Unaudited)**

*(Dollars in millions)*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Segment Net Sales**<sup>1</sup> |  |  |  | **Three Months** |  |
|  |  |  |  | **Ended** | **Sequential** |
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Increase /** | **March 31,** | **Increase /** |
|  | **2025** | **2024** | **(Decrease)** | **2025** | **(Decrease)** |
| Thermal & Specialized Solutions | $597 | $519 | $78 | $466 | $131 |
| Titanium Technologies | 657 | 677 | (20) | 597 | 60 |
| Advanced Performance Materials | 346 | 345 | 1 | 294 | 52 |
| Other Non-Reportable Segment | 15 | 13 | 2 | 11 | 4 |
| **Total Net Sales** | $1615 | $1554 | $61 | $1368 | $247 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Segment Adjusted EBITDA**<sup>1</sup> | **Segment Adjusted EBITDA**<sup>1</sup> |  |  | **Three Months** |  |
|  |  |  |  | **Ended** | **Sequential** |
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Increase /** | **March 31,** | **Increase /** |
|  | **2025** | **2024** | **(Decrease)** | **2025** | **(Decrease)** |
| Thermal & Specialized Solutions | $207 | $160 | $47 | $141 | $66 |
| Titanium Technologies | $47 | $83 | $(36) | $50 | $(3) |
| Advanced Performance Materials | $50 | $45 | $5 | $32 | $18 |
| Other Non-Reportable Segment | $4 | $3 | $1 | $1 | $3 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Quarterly Change in Net Sales from the three months ended June 30, 2024** | **Quarterly Change in Net Sales from the three months ended June 30, 2024** | **Quarterly Change in Net Sales from the three months ended June 30, 2024** | **Quarterly Change in Net Sales from the three months ended June 30, 2024** | **Quarterly Change in Net Sales from the three months ended June 30, 2024** | **Quarterly Change in Net Sales from the three months ended June 30, 2024** | **Quarterly Change in Net Sales from the three months ended June 30, 2024** |
|  | **June 30, 2025** | **Percentage Change vs.** | **Percentage Change Due To** | **Percentage Change Due To** | **Percentage Change Due To** | **Percentage Change Due To** |
|  | **Net Sales** | **June 30, 2024** | **Price** | **Volume** | **Currency** | **Portfolio** |
| Total Company | $1615 | 4% | 1% | 3% | —% | —% |
| Thermal & Specialized Solutions | $597 | 15% | 4% | 11% | —% | —% |
| Titanium Technologies | 657 | (3)% | (4)% | —% | 1% | —% |
| Advanced Performance Materials | 346 | —% | 6% | (6)% | —% | —% |
| Other Non-Reportable Segment | 15 | 15% | 1% | 14% | —% | —% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** | **Quarterly Change in Net Sales from the three months ended March 31, 2025** |
|  | **June 30, 2025** | **Percentage Change vs.** | **Percentage Change Due To** | **Percentage Change Due To** | **Percentage Change Due To** | **Percentage Change Due To** |
|  | **Net Sales** | **March 31, 2025** | **Price** | **Volume** | **Currency** | **Portfolio** |
| Total Company | $1615 | 18% | 3% | 14% | 1% | —% |
| Thermal & Specialized Solutions | $597 | 28% | 8% | 19% | 1% | —% |
| Titanium Technologies | 657 | 10% | (1)% | 9% | 2% | —% |
| Advanced Performance Materials | 346 | 18% | 2% | 14% | 2% | —% |
| Other Non-Reportable Segment | 15 | 36% | (1)% | 37% | —% | —% |

---

------

**The Chemours Company**

**Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)**

*(Dollars in millions)*

**<u>GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation</u>**

 **<u>GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation</u>**<sup>1</sup>

Adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") is defined as (loss) income before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net (loss) income attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** | **Twelve Months Ended** | **Twelve Months Ended** |
|  | **June 30,** | **June 30,** | **March 31,** | **June 30,** | **June 30,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2025** | **2024** | **2025** | **2024** |
| **(Loss) income before income taxes** | $(261) | $69 | $— | $(262) | $138 | (292) | 79 |
| **Net (loss) income attributable to Chemours** | $(381) | $60 | $(4) | $(385) | $113 | (427) | 106 |
| Non-operating pension and other post-retirement benefit income | (2) | (2) | (2) | (4) | (2) | (5) | (3) |
| Exchange losses, net | 4 | 7 | 3 | 7 | 6 | 10 | 32 |
| Restructuring, asset-related, and other charges (1) | 18 | 3 | 32 | 50 | 7 | 100 | 145 |
| Goodwill impairment charge (2) |  |  |  |  |  | 56 |  |
| Loss on extinguishment of debt |  |  |  |  |  | 1 | 1 |
| Gain on sales of assets and businesses, net (3) |  |  | (1) | (1) | (3) | (1) | (113) |
| Transaction costs (4) | 2 |  |  | 2 |  | 4 | 16 |
| Qualified spend recovery (5) | (13) | (8) | (9) | (22) | (15) | (33) | (37) |
| Litigation-related charges (6) | 299 | (1) |  | 299 | (6) | 302 | 112 |
| Environmental charges (7) | 60 |  |  | 60 |  | 75 | 8 |
| Adjustments made to income taxes (8) | 171 | (4) |  | 172 | (3) | 178 | (17) |
| (Benefit from) provision for income taxes relating to reconciling items (9) | (71) | 3 |  | (71) | 8 | (83) | (38) |
| **Adjusted Net Income** | 87 | 58 | 19 | 107 | 105 | 177 | 212 |
| Net income attributable to non-controlling interests | 1 |  |  | 1 |  | 1 |  |
| Interest expense, net | 67 | 66 | 66 | 133 | 128 | 268 | 247 |
| Depreciation and amortization (10) | 79 | 74 | 77 | 157 | 145 | 304 | 297 |
| All remaining provision for income taxes (9) | 19 | 9 | 4 | 21 | 20 | 39 | 28 |
| **Adjusted EBITDA** | $253 | $207 | $166 | $419 | $398 | $789 | $784 |
| Total debt principal |  |  |  |  |  | 4177 | 4028 |
| Less: Cash and cash equivalents |  |  |  |  |  | (502) | (604) |
| **Total debt principal, net** |  |  |  |  |  | $3675 | $3424 |
| **Net Leverage Ratio (calculated using GAAP earnings) (11)** |  |  |  |  |  | (12.6)x | 43.3x |
| **Net Leverage Ratio (calculated using Non-GAAP earnings) (11)** |  |  |  |  |  | 4.7x | 4.4x |

---

------

**<u>GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation</u>**

 **<u>GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued)</u>**<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)For the twelve months ended June 30, 2025, restructuring, asset-related and other charges primarily includes charges related to our decision to exit our SPS Capstone<sup>TM</sup> business and the 2024 Restructuring Program. For the twelve months ended June 30, 2024, restructuring, asset-related and other charges primarily includes charges related to the Titanium Technologies Transformation Plan, shutdown of a production line at the Company's El Dorado site and charges related to the 2023 Restructuring Program. See "Note 4 – Restructuring, Asset-Related and Other Charges" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Represents a non-cash goodwill impairment charge in the Advanced Performance Materials unit, which is discussed further in "Note 15 – Goodwill and Other Intangibles, Net" to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)For the twelve months ended June 30, 2024, gain on sales of assets and businesses, net includes pre-tax gain on sale of $106 million related to the Glycolic Acid Transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)For the twelve months ended June 30, 2024, transaction costs includes $7 million of costs associated with the Senior Secured Credit Facilities entered into during 2023 and $9 million of third-party costs related to the Titanium Technologies Transformation Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 16 – Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)Litigation-related charges pertains to litigation settlements, PFOA drinking water treatment accruals, and other related legal fees. For the twelve months ended June 30, 2025, litigation-related charges includes $257 million related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of New Jersey's settlement agreement reached in August 2025, $16 million of third-party legal fees directly related to the New Jersey settlement agreement, $14 million related to the Company's portion of Chemours and EID's settlement agreement to resolve the Hoosick Falls class action law suit, $12 million related to reserves for asbestos and production liability matters arising from an EID subsidiary, Sporting Goods Properties, Inc., and a $29 million accrual associated with the Ohio MDL, partially offset by $26 million of benefits from insurance recoveries. For the twelve months ended June 30, 2024, litigation-related charges includes a $7 million benefit related to insurance recoveries, $55 million of charges related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of Ohio's agreement entered into in November 2023, $13 million related to the Company's portion of the supplemental payment to the State of Delaware, $48 million for other PFAS litigation matters, and $3 million of other litigation matters. See "Note 16 – Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)Environmental charges pertains to management's assessment of estimated liabilities associated with certain remediation expenses at various sites. For the twelve months ended June 30, 2025, environmental charges primarily includes changes to remediation reserves at the four sites covered by the New Jersey settlement agreement and off-site remediation costs at Dordrecht Works. See "Note 16 – Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8)Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9)The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10)Accelerated depreciation charges of $12 million and $23 million incurred as part of our decision to exit our SPS Capstone<sup>TM</sup> business are included within the "Restructuring, asset-related and other charges" caption above, and therefore are not included as separate adjustment within this caption.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(11)Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by (loss) income before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.

------

**The Chemours Company**

**Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)**

*(Dollars in millions, except per share amounts)*

**<u>GAAP Earnings per Share to Adjusted Earnings per Share Reconciliation</u>**<sup>1</sup>

Adjusted earnings per share ("Adjusted EPS") is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which includes unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** | **March 31,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2025** | **2024** |
| Numerator: |  |  |  |  |  |
| &nbsp;&nbsp;Net (loss) income attributable to Chemours | $(381) | $60 | $(4) | $(385) | $113 |
| &nbsp;&nbsp;Adjusted Net Income | 87 | 58 | 19 | 107 | 105 |
| Denominator: |  |  |  |  |  |
| &nbsp;&nbsp;Weighted-average number of common shares outstanding - basic | 150238691 | 149413167 | 149918386 | 150078085 | 149224183 |
| &nbsp;&nbsp;Dilutive effect of the Company's employee compensation plans (1) | 268070 | 709893 | 491194 | 379632 | 862531 |
| &nbsp;&nbsp;Weighted-average number of common shares outstanding - diluted (1) | 150506761 | 150123060 | 150409580 | 150457717 | 150086714 |
| Basic (loss) earnings per share of common stock (2) | $(2.54) | $0.40 | $(0.03) | $(2.56) | $0.76 |
| Diluted (loss) earnings per share of common stock (1) (2) | (2.54) | 0.39 | (0.03) | (2.56) | 0.75 |
| Adjusted basic earnings per share of common stock (2) | 0.58 | 0.39 | 0.13 | 0.71 | 0.70 |
| Adjusted diluted earnings per share of common stock (1) (2) | 0.58 | 0.38 | 0.13 | 0.71 | 0.70 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three and six months ended June 30, 2025 and the three months ended March 31, 2025. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three and six months ended June 30, 2025 and the three months ended March 31, 2025 as Adjusted Net Income was in a net income position.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Figures may not recalculate exactly due to rounding. Basic and diluted (loss) earnings per share are calculated based on unrounded numbers.

**<u>GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation</u>** 

<br> Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** | **March 31,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2025** | **2024** |
| Cash flows provided by (used for) operating activities | $93 | $(620) | $(112) | $(19) | $(910) |
| Less: Purchases of property, plant, and equipment | (43) | (73) | (84) | (127) | (175) |
| **Free Cash Flows** | $50 | $(693) | $(196) | $(146) | $(1085) |
| Adjusted EBITDA | 253 | 207 | 166 | 419 | 398 |
| **Free Cash Flow Conversion** | 20% | (335)% | (118)% | (35)% | (273)% |

---

------

**The Chemours Company**

**Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)**

*(Dollars in millions, except per share amounts)*

**<u>2025 Estimated GAAP Net Loss Attributable to Chemours to Estimated Adjusted Net Income and Estimated Adjusted EBITDA Reconciliation (1)</u>** 

---

| | | |
|:---|:---|:---|
|  | **(Estimated)** | **(Estimated)** |
|  | **Year Ending December 31, 2025** | **Year Ending December 31, 2025** |
|  | **Low** | **High** |
| **Net loss attributable to Chemours** | $(336) | $(300) |
| Restructuring, transaction, and other costs, net (2) | 492 | 492 |
| **Adjusted Net Income** | 156 | 192 |
| Interest expense, net | 272 | 272 |
| Depreciation and amortization | 313 | 313 |
| All remaining provision for income taxes | 34 | 48 |
| **Adjusted EBITDA** | $775 | $825 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these estimates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Restructuring, transaction, and other costs, net includes the net benefit from income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.

------

## Exhibit 99.2

**EXHIBIT 99.2**

![img16331910_0.jpg](img16331910_0.jpg)

**Q2 2025 Financial Prepared Remarks**

*Comments made in these remarks, as well as in the supplemental information provided on our website, contain forward-looking statements that involve risks and uncertainties as described in The Chemours Company's (the "Company") SEC filings. These forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events that may not be realized. Actual results may differ, and Chemours undertakes no duty to update any forward-looking statements as a result of future developments or new information.*

*Within these prepared remarks, we will refer to certain non-GAAP financial measures*<sup>1</sup> *that we believe are useful to investors evaluating the company's performance.* 

**Shane Hostetter, Senior Vice President & Chief Financial Officer, The Chemours Company**

***Q2 2025 Earnings Supplement Presentation -- Chart 4: Second Quarter 2025 Financial Summary; Chart 5: Adjusted EBITDA Bridge: 2Q25 versus 2Q24***<sup>2</sup>

Our Consolidated Net Sales for the Second Quarter were approximately $1.6 billion, which was a 4% increase compared to the prior-year, and driven by a 3% increase in volume and 1% increase in price. The increase in volumes was primarily driven by increased Opteon™ Refrigerant blends volumes in TSS. Increased pricing was driven by stronger aftermarket demand for Opteon™ Refrigerant blends in TSS and strong pricing in APM's Advanced Materials portfolio, partially offset by TT pricing.

For the Second Quarter, Chemours reported a Net Loss of $381 million, or $2.54 cents per diluted share, compared to Net Income of $60 million, or $0.39 cents per diluted share, in the prior-year quarter, primarily driven by litigation-related charges pertaining to the announced settlement with the State of New Jersey<sup>3</sup>and related tax impacts.

For the Second Quarter, Adjusted EBITDA was $253 million, up from $207 million in the prior-year. This increase was primarily driven by the referenced volume and pricing dynamics alongside lower Corporate Expenses, which were partially offset by higher input and operational costs in TT, lower fixed cost absorption in APM, and minor input cost increases in TSS.

Now, let's turn to our business segment performance, starting with TSS.

***Chart 6: Quarterly Segment Summary***

In the Second Quarter, TSS achieved Net Sales of $597 million, a 15% increase from the prior year. This growth in sales was primarily driven by an 11% volume increase and a 4% price increase, while the currency impact remained flat.

<sup>1</sup>Non-GAAP measures, including Adjusted Net Income, Adjusted EPS and Adjusted EBITDA referred to throughout, principally exclude the impact of recent litigation settlements for legacy environmental matters and associated fees, in addition to other unallocated items – please refer to the attached "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)".

<sup>2</sup>As previously disclosed in the first quarter of 2025, certain prior periods have been revised to correct for immaterial errors as further described in our Quarterly Report on Form 10-Q for the three months ended June 30, 2025.

<sup>3</sup>$257 million of litigation-related charges pertaining to the announced settlement with the state of New Jersey were recorded within Selling, general, and administrative expense for the second quarter of 2025.

------

**EXHIBIT 99.2**

![img16331910_0.jpg](img16331910_0.jpg)

The increase in TSS volumes was driven by a continued double-digit, 65% year-over-year sales growth in our Opteon™ Refrigerants, which reflects continued strength in blends demand, driven by the transition of stationary air conditioning ("AC") equipment under the U.S. AIM Act. This growth was partially offset by a decrease in volume for our Freon™ Refrigerants portfolio in connection with this regulatory transition. The increase in pricing year-over-year was primarily driven by the stronger Opteon™ Refrigerant aftermarket demand.

Second Quarter Adjusted EBITDA for TSS increased by 29% to $207 million compared to the prior year. Adjusted EBITDA margin of 35% also increased by four percentage points. This increase was primarily driven by the previously referenced increases in volume and price tied to demand for Opteon™ Refrigerant blends products in connection with the stationary AC transition, partially offset by minor input cost increases.

Sequentially, TSS Net Sales increased by 28%, driven by a 19% volume increase and an 8% price increase, with a slight 1% tailwind from currency. Overall volume and price increases were primarily related to typical seasonal trends across refrigerant products and the increased demand for Opteon™ Refrigerant blends in connection with the stationary AC transition under the U.S. AIM Act. Our increased pricing also reflects actions that the Company has taken to continue to offset cost headwinds related to certain input costs, which we referenced earlier in the year.

I should note that we see no changes in the momentum around the transition to low global warming potential refrigerants as the U.S. AIM Act progresses, and we continue to see a strong regulatory framework to drive the transition. At Chemours, we are now seeing Opteon™ Refrigerants make up 75% of total refrigerant revenues, up from 57% in the prior-year quarter, and we feel well-positioned in the market.

Now, let's move to our TT segment…

In the Second Quarter, TT's Net Sales decreased 3% year-over-year to $657 million, primarily due to a 4% decrease in price globally, partially offset by favorable currency movement that created a 1% tailwind. Volumes remained generally flat overall, with stronger demand in North America and Europe offsetting lower volumes in other non-western markets.

TT's Second Quarter Adjusted EBITDA decreased 43% to $47 million compared to the prior year, with Adjusted EBITDA Margin declining five percentage points to 7%. The decline in Adjusted EBITDA was driven in part by the previously mentioned decrease in price, partially offset by favorable currency movements. TT operations were also disrupted by a now resolved external rail issue in the Second Quarter of 2025, which impacted feedstock mix, while also experiencing unrelated operational disruptions. In order to supply its customers, the Company elected to consume higher-cost ore feedstock, which resulted in incremental costs of $15 million in the second quarter. The net costs associated with other operational disruptions were $8 million for the quarter.

Sequentially, TT's Second Quarter Net Sales increased by 10%, driven by a 9% increase in volume across all regions, partially offset by a 1% decrease in price, with a favorable 2% currency tailwind.

------

**EXHIBIT 99.2**

![img16331910_0.jpg](img16331910_0.jpg)

Turning to our APM segment…

In the Second Quarter of 2025, APM reported Net Sales of $346 million, in line with the prior year. A 6% increase in price was primarily attributable to stronger pricing into high-value applications as well as pricing opportunities associated with the SPS Capstone™ product exit<sup>4</sup>. The price increase was offset by a 6% decrease in volume, primarily driven by weakness in cyclical end markets impacting Advanced Materials and products serving the hydrogen markets under Performance Solutions, while currency impact remained flat.

APM's Second Quarter Adjusted EBITDA increased 11% to $50 million compared to the prior year, with Adjusted EBITDA margin increasing by one percentage point to 14%. The increase was primarily due to the referenced increase in price, partially offset by lower fixed cost absorption due to lower overall volumes.

Sequentially, APM's Second Quarter Net Sales increased by 18%, driven by a 14% volume increase and a 2% increase in price, with a favorable 2% currency tailwind.

Moving to our Other Non-Reportable Segment, we recorded Net Sales of $15 million and Adjusted EBITDA of $4 million in the Second Quarter.

Lastly, our Corporate Expenses as an offset to our Adjusted EBITDA totaled $53 million in the Second Quarter, a decrease compared to the prior-year. The decrease in the quarter was primarily due to lower costs associated with the Audit Committee's prior year internal review and the 2024 material weakness remediation.

***Chart 7: Liquidity Position as of June 30, 2025***

Turning to our liquidity, as of June 30, 2025, our consolidated gross debt stood at $4.2 billion, with approximately $1.5 billion in total liquidity. This includes $502 million in unrestricted cash and cash equivalents, along with approximately $954 million available under our revolving credit facility, net of outstanding letters of credit. Additionally, the Company retained $51 million in restricted cash and cash equivalents, all of which is held in escrow under the terms of the Memorandum of Understanding related to potential future legacy liabilities. The combination of the expected release of restricted cash and the $150 million from the insurance proceeds MOU is expected to fully fund the $200 million in payment obligations of Chemours for the New Jersey settlement through at least 2030. On a trailing twelve-month basis, our net leverage was 4.7 times Adjusted EBITDA, reflecting a decrease sequentially compared to 5.0 times as of March 31, 2025. Management anticipates progressive net leverage improvements to continue throughout 2025.

Regarding our cash flow for the Second Quarter, cash provided by operating activities was $93 million, compared to operating cash usage of $620 million in the prior-year quarter. The improvement in operating cash outflows was primarily due to the release of the $606 million of restricted cash and restricted cash equivalents deposited in the qualified settlement fund per the terms of the U.S. public water system settlement agreement.

<sup>4</sup>In January 2025, under the Portfolio Management pillar of Pathway to Thrive, as a part of a broader strategic review of our APM European asset footprint, APM management approved a restructuring program to exit its SPS Capstone™ business. This timing remains on track anticipating final sales in the third quarter of 2025.

------

**EXHIBIT 99.2**

![img16331910_0.jpg](img16331910_0.jpg)

Capital expenditures for the quarter totaled $43 million, a decrease compared to $73 million in the prior-year quarter. This decrease was driven by lower capital expenditures in APM and TSS due to the completion of key growth projects in both of those businesses earlier this year. Free Cash Flow reflected a positive $50 million. Additionally, the Company paid $13 million in dividends to shareholders during the quarter.

***Appendix, Chart 22: Actual and Projected Disruption & Investment Costs (Unaudited)***

In connection with those costs incurred in recent quarters from business disruptions and other investments, we've captured a summary in our charts to help frame out these impacts. While these costs are included as a part of our Adjusted EBITDA, we do view these as operational areas where we can drive further improvement and reduce the impact of going forward. In addition, we wanted to highlight the continued investments that we're making in the TSS business to develop our immersion cooling and next-generation refrigerants.

***Non-GAAP Financial Measures*** 

*We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within these remarks, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.*

*Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.*

------

**EXHIBIT 99.2**

![img16331910_0.jpg](img16331910_0.jpg)

***Forward-Looking Statements***

*These remarks contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the Company's performance for the second quarter of 2025, the transition to low global warming potential refrigerants and the Company's refreshed corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, any future insurance recoveries, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the US or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.*

------

**The Chemours Company**

**Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)**

*(Dollars in millions)*

**<u>GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation</u>**

 **<u>GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation</u>**<sup>1</sup>

Adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") is defined as (loss) income before income taxes, excluding the following items: interest expense, depreciation, and amortization; non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension costs excluding the service cost component; exchange (gains) losses included in other income (expense), net; restructuring, asset-related, and other charges; (gains) losses on sales of businesses or assets; and, other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of the Company's cost-sharing agreement under the terms of the MOU that were previously excluded from Adjusted EBITDA. Adjusted Net Income is defined as net (loss) income attributable to Chemours, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** | **Twelve Months Ended** | **Twelve Months Ended** |
|  | **June 30,** | **June 30,** | **March 31,** | **June 30,** | **June 30,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2025** | **2024** | **2025** | **2024** |
| **(Loss) income before income taxes** | $(261) | $69 | $— | $(262) | $138 | (292) | 79 |
| **Net (loss) income attributable to Chemours** | $(381) | $60 | $(4) | $(385) | $113 | (427) | 106 |
| Non-operating pension and other post-retirement benefit income | (2) | (2) | (2) | (4) | (2) | (5) | (3) |
| Exchange losses, net | 4 | 7 | 3 | 7 | 6 | 10 | 32 |
| Restructuring, asset-related, and other charges (1) | 18 | 3 | 32 | 50 | 7 | 100 | 145 |
| Goodwill impairment charge (2) |  |  |  |  |  | 56 |  |
| Loss on extinguishment of debt |  |  |  |  |  | 1 | 1 |
| Gain on sales of assets and businesses, net (3) |  |  | (1) | (1) | (3) | (1) | (113) |
| Transaction costs (4) | 2 |  |  | 2 |  | 4 | 16 |
| Qualified spend recovery (5) | (13) | (8) | (9) | (22) | (15) | (33) | (37) |
| Litigation-related charges (6) | 299 | (1) |  | 299 | (6) | 302 | 112 |
| Environmental charges (7) | 60 |  |  | 60 |  | 75 | 8 |
| Adjustments made to income taxes (8) | 171 | (4) |  | 172 | (3) | 178 | (17) |
| (Benefit from) provision for income taxes relating to reconciling items (9) | (71) | 3 |  | (71) | 8 | (83) | (38) |
| **Adjusted Net Income** | 87 | 58 | 19 | 107 | 105 | 177 | 212 |
| Net income attributable to non-controlling interests | 1 |  |  | 1 |  | 1 |  |
| Interest expense, net | 67 | 66 | 66 | 133 | 128 | 268 | 247 |
| Depreciation and amortization (10) | 79 | 74 | 77 | 157 | 145 | 304 | 297 |
| All remaining provision for income taxes (9) | 19 | 9 | 4 | 21 | 20 | 39 | 28 |
| **Adjusted EBITDA** | $253 | $207 | $166 | $419 | $398 | $789 | $784 |
| Total debt principal |  |  |  |  |  | 4177 | 4028 |
| Less: Cash and cash equivalents |  |  |  |  |  | (502) | (604) |
| **Total debt principal, net** |  |  |  |  |  | $3675 | $3424 |
| **Net Leverage Ratio (calculated using GAAP earnings) (11)** |  |  |  |  |  | (12.6)x | 43.3x |
| **Net Leverage Ratio (calculated using Non-GAAP earnings) (11)** |  |  |  |  |  | 4.7x | 4.4x |

---

------

**<u>GAAP Net (Loss) Income Attributable to Chemours to Adjusted Net Income and Adjusted EBITDA Reconciliation</u>**

 **<u>GAAP Net Leverage Ratio to Non-GAAP Net Leverage Ratio Reconciliation (Continued)</u>**<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)For the twelve months ended June 30, 2025, restructuring, asset-related and other charges primarily includes charges related to our decision to exit our SPS Capstone<sup>TM</sup> business and the 2024 Restructuring Program. For the twelve months ended June 30, 2024, restructuring, asset-related and other charges primarily includes charges related to the Titanium Technologies Transformation Plan, shutdown of a production line at the Company's El Dorado site and charges related to the 2023 Restructuring Program. See "Note 4 – Restructuring, Asset-Related and Other Charges" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Represents a non-cash goodwill impairment charge in the Advanced Performance Materials unit, which is discussed further in "Note 15 – Goodwill and Other Intangibles, Net" to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)For the twelve months ended June 30, 2024, gain on sales of assets and businesses, net includes pre-tax gain on sale of $106 million related to the Glycolic Acid Transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)For the twelve months ended June 30, 2024, transaction costs includes $7 million of costs associated with the Senior Secured Credit Facilities entered into during 2023 and $9 million of third-party costs related to the Titanium Technologies Transformation Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Qualified spend recovery represents costs and expenses that were previously excluded from Adjusted EBITDA, reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the MOU which is discussed in further detail in "Note 16 – Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)Litigation-related charges pertains to litigation settlements, PFOA drinking water treatment accruals, and other related legal fees. For the twelve months ended June 30, 2025, litigation-related charges includes $257 million related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of New Jersey's settlement agreement reached in August 2025, $16 million of third-party legal fees directly related to the New Jersey settlement agreement, $14 million related to the Company's portion of Chemours and EID's settlement agreement to resolve the Hoosick Falls class action law suit, $12 million related to reserves for asbestos and production liability matters arising from an EID subsidiary, Sporting Goods Properties, Inc., and a $29 million accrual associated with the Ohio MDL, partially offset by $26 million of benefits from insurance recoveries. For the twelve months ended June 30, 2024, litigation-related charges includes a $7 million benefit related to insurance recoveries, $55 million of charges related to the Company's portion of Chemours, DuPont, Corteva, EID and the State of Ohio's agreement entered into in November 2023, $13 million related to the Company's portion of the supplemental payment to the State of Delaware, $48 million for other PFAS litigation matters, and $3 million of other litigation matters. See "Note 16 – Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)Environmental charges pertains to management's assessment of estimated liabilities associated with certain remediation expenses at various sites. For the twelve months ended June 30, 2025, environmental charges primarily includes changes to remediation reserves at the four sites covered by the New Jersey settlement agreement and off-site remediation costs at Dordrecht Works. See "Note 16 – Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements* in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 for further details.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8)Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as shortfalls and windfalls on our share-based payments, certain return-to-accrual adjustments, valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9)The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred for each of the reconciling items and represent both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10)Accelerated depreciation charges of $12 million and $23 million incurred as part of our decision to exit our SPS Capstone<sup>TM</sup> business are included within the "Restructuring, asset-related and other charges" caption above, and therefore are not included as separate adjustment within this caption.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(11)Net Leverage Ratio calculated using GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by (loss) income before income taxes. Net Leverage Ratio calculated using non-GAAP measures is defined as our total debt principal, net, or our total debt principal outstanding less unrestricted cash and cash equivalents, divided by Adjusted EBITDA.

------

**The Chemours Company**

**Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)**

*(Dollars in millions, except per share amounts)*

**<u>GAAP Earnings per Share to Adjusted Earnings per Share Reconciliation</u>**<sup>1</sup>

Adjusted earnings per share ("Adjusted EPS") is calculated by dividing Adjusted Net Income by the weighted-average number of common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of stock-based compensation awards, which includes unvested restricted shares. Diluted Adjusted EPS considers the impact of potentially-dilutive securities, except in periods in which there is a loss because the inclusion of the potentially-dilutive securities would have an anti-dilutive effect.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** | **March 31,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2025** | **2024** |
| Numerator: |  |  |  |  |  |
| &nbsp;&nbsp;Net (loss) income attributable to Chemours | $(381) | $60 | $(4) | $(385) | $113 |
| &nbsp;&nbsp;Adjusted Net Income | 87 | 58 | 19 | 107 | 105 |
| Denominator: |  |  |  |  |  |
| &nbsp;&nbsp;Weighted-average number of common shares outstanding - basic | 150238691 | 149413167 | 149918386 | 150078085 | 149224183 |
| &nbsp;&nbsp;Dilutive effect of the Company's employee compensation plans (1) | 268070 | 709893 | 491194 | 379632 | 862531 |
| &nbsp;&nbsp;Weighted-average number of common shares outstanding - diluted (1) | 150506761 | 150123060 | 150409580 | 150457717 | 150086714 |
| Basic (loss) earnings per share of common stock (2) | $(2.54) | $0.40 | $(0.03) | $(2.56) | $0.76 |
| Diluted (loss) earnings per share of common stock (1) (2) | (2.54) | 0.39 | (0.03) | (2.56) | 0.75 |
| Adjusted basic earnings per share of common stock (2) | 0.58 | 0.39 | 0.13 | 0.71 | 0.70 |
| Adjusted diluted earnings per share of common stock (1) (2) | 0.58 | 0.38 | 0.13 | 0.71 | 0.70 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)In periods where the Company incurs a net loss, the impact of potentially dilutive securities is excluded from the calculation of EPS under U.S. GAAP, as their inclusion would have an anti-dilutive effect. As such, with respect to the U.S. GAAP measure of diluted EPS, the impact of potentially dilutive securities is excluded from our calculation for the three and six months ended June 30, 2025 and the three months ended March 31, 2025. With respect to the non-GAAP measure of adjusted diluted EPS, the impact of potentially dilutive securities is included in our calculation for the three and six months ended June 30, 2025 and the three months ended March 31, 2025 as Adjusted Net Income was in a net income position.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Figures may not recalculate exactly due to rounding. Basic and diluted (loss) earnings per share are calculated based on unrounded numbers.

**<u>GAAP Cash Flow Provided by Operating Activities to Free Cash Flows and Free Cash Flow Conversion Reconciliation</u>** 

<br> Free Cash Flows is defined as cash flows provided by (used for) operating activities, less purchases of property, plant and equipment as shown in the consolidated statements of cash flows. Free Cash Flow Conversion is calculated as the percentage of Free Cash Flows to Adjusted EBITDA.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **June 30,** | **June 30,** | **March 31,** | **June 30,** | **June 30,** |
|  | **2025** | **2024** | **2025** | **2025** | **2024** |
| Cash flows provided by (used for) operating activities | $93 | $(620) | $(112) | $(19) | $(910) |
| Less: Purchases of property, plant, and equipment | (43) | (73) | (84) | (127) | (175) |
| **Free Cash Flows** | $50 | $(693) | $(196) | $(146) | $(1085) |
| Adjusted EBITDA | 253 | 207 | 166 | 419 | 398 |
| **Free Cash Flow Conversion** | 20% | (335)% | (118)% | (35)% | (273)% |

---

------